Freya Biosciences Highlights Clinical Progress in Women’s Health Program

According to a recent LinkedIn post from Freya Biosciences, members of the company’s science team plan to attend the Microbes in Women’s Health Congress in Valencia, Spain, on April 21–22. The post notes that CSO and co‑founder Johan E.T. van Hylckama Vlieg is expected to participate in discussions with peers focused on women’s health.

The company’s LinkedIn post highlights its work on disease‑modifying therapies aimed at inflammation and immune dysregulation to address unmet needs in women’s health. It also references recently announced Phase 1 first‑in‑human data for lead candidate FB301 in IVF‑related embryo implantation failure, suggesting early clinical progress that may support future funding, partnership interest, and validation of its microbiome‑based therapeutic approach.